Introduction Acute promyelocytic leukemia with t(15;17) is a cancerous disease of the white blood cells in the bone marrow and peripheral blood.
What does APML stand for?
APML stands for Acute Promyelocytic Leukemia
This definition appears very frequently and is found in the following Acronym Finder categories:
- Science, medicine, engineering, etc.
See other definitions of APML
We have 18 other meanings of APML in our Acronym Attic
- Department of Anaesthetics, Pain Medicine and Intensive Care (Imperial College; UK)
- Associate Parliamentary Manufacturing Industry Group (UK)
- Andhra Pradesh Micro Irrigation Project (Andhra Pradesh, India)
- Airborne Polarimetric Microwave Imaging Radiometer
- Acta Pathol Microbiol Immunol Scand
- Acta Pathologica, Microbiologica et Immunologica Scandinavica
- Automated Project Management Information System
- Automated Project Management System
- Asian and Pacific Migration Journal
- Acquisition Program Manager for Logistics
- Adaptive Pseudo-Maximum-Likelihood (data estimation algorithm)
- Advanced Platform Management Link (server)
- Anisotropic Perfectly Matched Layer
- Assistant Program Manager for Logistics
- Associate Program Manager for Logistics
- Attention Profiling Mark-up Language
- Alteração Positiva Moderada de Longa Duração (Portuguese: Moderate Positive Change Long Term; Brazil)
- Activity Planning and Management Model
- AP Moller Maersk (Copenhagen, Denmark)
- Arthroscopic Partial Medial Meniscectomy (medical procedure)
Samples in periodicals archive:
Arsenic trioxide has been used as a mitochondria-targeting drug in acute promyelocytic leukemia (Jimi et al.
Acute promyelocytic leukemia (APL) is caused by inhibition of apoptosis and a block in myeloid differentiation resulting from a translocation invariably involving the retinoic acid a (RAR[alpha]) gene (1,2).
Seattle, WA; 206-282-7100), announced that the European Commission has granted the Marketing Authorization for TRISENOX (arsenic trioxide), indicated for the induction of remission and consolidation in adult patients with relapsed/refractory acute promyelocytic leukemia characterized by the presence of the t(15:17) translocation and/or the presence of the Pro-Myelocytic Leukemia/Retinioic-Acid-Receptor-alpha (PML/RAR-alpha) gene.